Jeff Jones
Stock Analyst at Oppenheimer
(4.72)
# 691
Out of 4,468 analysts
274
Total ratings
45.5%
Success rate
21.4%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Reiterated: Buy | $55 | $26.50 | +107.55% | 13 | Jun 26, 2026 | |
| ODTX Odyssey Therapeutics | Reiterated: Buy | $40 | $16.74 | +138.95% | 2 | Jun 18, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $54 → $52 | $9.25 | +462.16% | 23 | Jun 17, 2026 | |
| ACRV Acrivon Therapeutics | Initiated Coverage: Buy | $8 | $1.72 | +365.12% | 1 | Jun 15, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $45 | $18.19 | +147.39% | 1 | Jun 15, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $13 | $3.63 | +258.13% | 31 | Jun 1, 2026 | |
| AVBP ArriVent BioPharma | Reiterated: Buy | $50 | $34.67 | +44.22% | 8 | Jun 1, 2026 | |
| MDWD MediWound | Maintained: Buy | $34 → $32 | $15.17 | +111.01% | 5 | May 28, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterated: Buy | $33 | $15.23 | +116.68% | 17 | May 15, 2026 | |
| CMMB Chemomab Therapeutics | Maintained: Buy | $25 | $2.27 | +1,001.32% | 22 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 → $66 | $25.77 | +156.11% | 8 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $1.22 | +309.84% | 16 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $33.86 | +47.67% | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $5.56 | +79.86% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $4.19 | +67.06% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $41 → $40 | $13.77 | +190.49% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 | $32.49 | +164.70% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.81 | - | 20 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $113.51 | +5.72% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $5.17 | +209.48% | 4 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $20 | $6.40 | +212.50% | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.16 | - | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.74 | n/a | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $4.42 | n/a | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.64 | n/a | 5 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.97 | n/a | 4 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.06 | n/a | 4 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $3.41 | n/a | 3 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 2 | Jul 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.002 | n/a | 1 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $52.62 | n/a | 1 | Jun 22, 2021 |
Alumis
Jun 26, 2026
Reiterated: Buy
Price Target: $55
Current: $26.50
Upside: +107.55%
Odyssey Therapeutics
Jun 18, 2026
Reiterated: Buy
Price Target: $40
Current: $16.74
Upside: +138.95%
Corbus Pharmaceuticals Holdings
Jun 17, 2026
Reiterated: Buy
Price Target: $54 → $52
Current: $9.25
Upside: +462.16%
Acrivon Therapeutics
Jun 15, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.72
Upside: +365.12%
Ascentage Pharma Group International
Jun 15, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $18.19
Upside: +147.39%
Perspective Therapeutics
Jun 1, 2026
Reiterated: Buy
Price Target: $13
Current: $3.63
Upside: +258.13%
ArriVent BioPharma
Jun 1, 2026
Reiterated: Buy
Price Target: $50
Current: $34.67
Upside: +44.22%
MediWound
May 28, 2026
Maintained: Buy
Price Target: $34 → $32
Current: $15.17
Upside: +111.01%
Corvus Pharmaceuticals
May 15, 2026
Reiterated: Buy
Price Target: $33
Current: $15.23
Upside: +116.68%
Chemomab Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $25
Current: $2.27
Upside: +1,001.32%
May 15, 2026
Reiterated: Buy
Price Target: $62 → $66
Current: $25.77
Upside: +156.11%
May 13, 2026
Maintained: Buy
Price Target: $6 → $5
Current: $1.22
Upside: +309.84%
May 13, 2026
Reiterated: Buy
Price Target: $50
Current: $33.86
Upside: +47.67%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $5.56
Upside: +79.86%
May 8, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $4.19
Upside: +67.06%
May 8, 2026
Maintained: Buy
Price Target: $41 → $40
Current: $13.77
Upside: +190.49%
Apr 20, 2026
Maintained: Buy
Price Target: $86
Current: $32.49
Upside: +164.70%
Mar 2, 2026
Rated: Hold
Price Target: n/a
Current: $2.81
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $120
Current: $113.51
Upside: +5.72%
Aug 15, 2025
Maintained: Buy
Price Target: $17 → $16
Current: $5.17
Upside: +209.48%
Aug 14, 2025
Maintained: Buy
Price Target: $19 → $20
Current: $6.40
Upside: +212.50%
Aug 8, 2025
Maintained: Hold
Price Target: n/a
Current: $1.16
Upside: -
Oct 29, 2024
Rated: Hold
Price Target: n/a
Current: $7.74
Upside: n/a
Aug 14, 2024
Maintained: Hold
Price Target: n/a
Current: $4.42
Upside: n/a
Nov 30, 2023
Maintained: Buy
Price Target: n/a
Current: $2.64
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: n/a
Current: $1.97
Upside: n/a
Nov 7, 2023
Maintained: Buy
Price Target: n/a
Current: $1.06
Upside: n/a
Apr 28, 2023
Rated: Buy
Price Target: n/a
Current: $3.41
Upside: n/a
Jul 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Sep 30, 2021
Reiterated: Hold
Price Target: n/a
Current: $0.002
Upside: n/a
Jun 22, 2021
Maintained: Buy
Price Target: $37
Current: $52.62
Upside: n/a